Breast cancer manifests in different stages according to the tumor size, node, metastasis (TNM) staging algorithm, along with tumor markers such as human epidermal growth factor 2 (HER2) and HR (hormone receptor), which can influence the choice of treatment regimen (6). This evidence concerns the gene ERBB2 and breast carcinoma.